Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways
- 7 March 2005
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (3), 337-345
- https://doi.org/10.1177/0091270004271969
Abstract
Two 14-day, randomized, open-label, parallel-group studies examined the effects of extended-release (ER) oxymorphone on CYP2C9 or CYP3A4 metabolic activities in healthy subjects. On days -1, 7, and 14, subjects received either a CYP2C9 probe (tolbutamide 500 mg) or CYP3A4 probes (midazolam and [14C N-methyl]-erythromycin for the erythromycin breath test). Subjects were randomized to 5 groups: high-dose oxymorphone ER (3 x 20 mg q12h) + naltrexone (50 mg q24h); low-dose oxymorphone ER (10-20 mg q12h); rifampin (2 x 300 mg q24h), an inducer of CYP2C9 and CYP3A4 activities; naltrexone (50 mg q24h); or CYP probes alone (controls). Probe metabolism was significantly altered by rifampin on days 7 and 14 (P < .05), whereas probe metabolism was not significantly affected by low-dose oxymorphone ER or by high-dose oxymorphone ER plus naltrexone. Oxymorphone ER exhibits a minimal potential for causing metabolic drug-drug interactions mediated by CYP2C9 or CYP3A4.Keywords
This publication has 7 references indexed in Scilit:
- Pharmacokinetics and Dose‐Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
- Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugsAmerican Journal Of Medicine, 2002
- Drug Interactions with Patient-Controlled AnalgesiaClinical Pharmacokinetics, 2002
- Drug Glucuronidation in Clinical PsychopharmacologyJournal of Clinical Psychopharmacology, 2001
- Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamideClinical Pharmacology & Therapeutics, 2001
- Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A ActivityThe Journal of Clinical Pharmacology, 1999
- Drug-Related Morbidity and MortalityArchives of Internal Medicine, 1995